US45258J1025
US45258J1025
Immunovant, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2026 | 2025 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 532.902.000 | 438.152.000 | 21.6% | |
| Operating Income | -532.902.000 | -438.152.000 | 21.6% |
| Pretax Income | -505.391.000 | -412.949.000 | 22.4% |
| Net Income Common Stockholders | -505.606.000 | -413.840.000 | 22.2% |
| -- | -- | -- | |
| -- | -- | -- |